At present, targeted therapies for metastatic CRC such as the angiogenesis inhibitor, bevacizumab, or the epidermal growth factor receptor (EGFR) inhibitor, cetuximab, have been used, but with only incremental effects [1–4]. Here, EGFR is linked to colorectal carcinoma.